DK1019446T3 - Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil - Google Patents

Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil

Info

Publication number
DK1019446T3
DK1019446T3 DK98903545T DK98903545T DK1019446T3 DK 1019446 T3 DK1019446 T3 DK 1019446T3 DK 98903545 T DK98903545 T DK 98903545T DK 98903545 T DK98903545 T DK 98903545T DK 1019446 T3 DK1019446 T3 DK 1019446T3
Authority
DK
Denmark
Prior art keywords
hydrogels
peg
hydrolytically degradable
crosslinked
precursors
Prior art date
Application number
DK98903545T
Other languages
English (en)
Other versions
DK1019446T4 (da
Inventor
J Milton Harris
Original Assignee
Debio Rech Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25455637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1019446(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Debio Rech Pharma Sa filed Critical Debio Rech Pharma Sa
Publication of DK1019446T3 publication Critical patent/DK1019446T3/da
Application granted granted Critical
Publication of DK1019446T4 publication Critical patent/DK1019446T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
DK98903545.6T 1997-09-12 1998-01-23 Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil DK1019446T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/928,049 US20020064546A1 (en) 1996-09-13 1997-09-12 Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
PCT/US1998/000920 WO1999014259A1 (en) 1997-09-12 1998-01-23 Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor

Publications (2)

Publication Number Publication Date
DK1019446T3 true DK1019446T3 (da) 2007-07-30
DK1019446T4 DK1019446T4 (da) 2012-03-19

Family

ID=25455637

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98903545.6T DK1019446T4 (da) 1997-09-12 1998-01-23 Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil

Country Status (11)

Country Link
US (2) US20020064546A1 (da)
EP (1) EP1019446B2 (da)
JP (1) JP4083384B2 (da)
AT (1) ATE358150T1 (da)
AU (1) AU6029398A (da)
CA (1) CA2303365C (da)
DE (1) DE69837443T3 (da)
DK (1) DK1019446T4 (da)
ES (1) ES2281925T5 (da)
PT (1) PT1019446E (da)
WO (1) WO1999014259A1 (da)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
AU4648697A (en) 1996-09-23 1998-04-14 Chandrashekar Pathak Methods and devices for preparing protein concentrates
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6258351B1 (en) * 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
US6371975B2 (en) 1998-11-06 2002-04-16 Neomend, Inc. Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US20030191496A1 (en) 1997-03-12 2003-10-09 Neomend, Inc. Vascular sealing device with microwave antenna
US7642323B2 (en) 1997-11-06 2010-01-05 Nektar Therapeutics Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US6514534B1 (en) 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US6458147B1 (en) 1998-11-06 2002-10-01 Neomend, Inc. Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US6994686B2 (en) 1998-08-26 2006-02-07 Neomend, Inc. Systems for applying cross-linked mechanical barriers
US6949114B2 (en) 1998-11-06 2005-09-27 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US7279001B2 (en) 1998-11-06 2007-10-09 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6899889B1 (en) 1998-11-06 2005-05-31 Neomend, Inc. Biocompatible material composition adaptable to diverse therapeutic indications
US8802146B2 (en) * 1998-11-06 2014-08-12 Neomend, Inc. Systems, methods, and compositions for prevention of tissue adhesion
US6830756B2 (en) 1998-11-06 2004-12-14 Neomend, Inc. Systems, methods, and compositions for achieving closure of vascular puncture sites
US6958212B1 (en) 1999-02-01 2005-10-25 Eidgenossische Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
CA2359318C (en) 1999-02-01 2009-06-30 Universitat Zurich Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US7008635B1 (en) 1999-09-10 2006-03-07 Genzyme Corporation Hydrogels for orthopedic repair
BR9917517A (pt) * 1999-10-08 2002-07-30 Shearwater Corp Derivados poliméricos heterobifuncionais e processo para a preparação dos mesmos
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
EP1355965B1 (en) 2000-10-19 2012-09-19 Ecole Polytechnique Fédérale de Lausanne (EPFL) Method of synthesizing block copolymers for multifunctional self-assembled systems
US7829074B2 (en) 2001-10-18 2010-11-09 Nektar Therapeutics Hydroxypatite-targeting poly(ethylene glycol) and related polymers
EP1421216A4 (en) * 2001-09-01 2006-05-17 Samsung Electronics Co Ltd PROCESS FOR PRODUCING A HYDROGEL BIOPUCE USING AN ETOILE POLYETHYLENE GLYCOL DERIVATIVE COMPRISING AN EPOXY GROUP
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
CA2822457C (en) 2001-12-14 2016-03-08 The University Of Wyoming Methods and compositions for controlled resease of drugs
AU2003270555B2 (en) * 2002-09-09 2009-01-29 Nektar Therapeutics Method for preparing water-soluble polymer derivatives bearing a terminal carboxylic acid
US7045552B2 (en) * 2002-09-27 2006-05-16 Trimeris, Inc. Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
JP2006523211A (ja) 2003-03-14 2006-10-12 ネオス テクノロジーズ インコーポレイテッド 分岐水溶性ポリマーとその複合物
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
AU2004240553A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US6787443B1 (en) * 2003-05-20 2004-09-07 Intel Corporation PCB design and method for providing vented blind vias
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005044839A2 (en) 2003-11-05 2005-05-19 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP2007517522A (ja) * 2004-01-07 2007-07-05 トリメリス，インコーポレーテッド ＨＩＶｇｐ４１ＨＲ２由来の合成ペプチド、およびヒト免疫不全ウイルスの伝播を阻止する治療におけるその使用
US7338933B2 (en) 2004-01-08 2008-03-04 Neose Technologies, Inc. O-linked glycosylation of peptides
US7282584B2 (en) 2004-06-16 2007-10-16 Straumann Holding Ag Methylene blue
ATE385423T1 (de) 2004-06-16 2008-02-15 Straumann Holding Ag Abdeckmembran
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
EP3061461A1 (en) 2004-10-29 2016-08-31 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US9029331B2 (en) 2005-01-10 2015-05-12 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
JP2008530305A (ja) 2005-02-09 2008-08-07 タイコ ヘルスケア グループ エルピー 合成封止剤
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
JP5329949B2 (ja) 2005-05-31 2013-10-30 エコーレ ポリテクニーク フェデラーレ デ ローザンヌ 遺伝子に基づいた薬物の細胞質送達のためのトリブロックコポリマー
US8367096B2 (en) 2005-07-19 2013-02-05 Boston Scientific Scimed, Inc. Polymers having covalently bound therapeutic agents
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
US8449714B2 (en) 2005-12-08 2013-05-28 Covidien Lp Biocompatible surgical compositions
EP1989220B1 (en) 2006-02-02 2011-12-14 Trimeris, Inc. Hiv fusion inhibitor peptides with improved biological properties
AU2007243483B2 (en) 2006-04-24 2012-07-26 Incept, Llc Protein crosslinkers, crosslinking methods and applications thereof
US7960498B2 (en) * 2006-06-30 2011-06-14 Actamax Surgical Materials, Llc Tissue adhesives with modified elasticity
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
BRPI0717505B8 (pt) 2006-10-04 2021-05-25 Novo Nordisk As conjugado de peptídeo e formulação farmacêutica
PL2118123T3 (pl) 2007-01-31 2016-06-30 Dana Farber Cancer Inst Inc Stabilizowane peptydy p53 i ich zastosowania
US20090227689A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
US20090227981A1 (en) * 2007-03-05 2009-09-10 Bennett Steven L Low-Swelling Biocompatible Hydrogels
JP5052919B2 (ja) * 2007-03-08 2012-10-17 成均▲館▼大學校 産學協力團 Ｐｈ及び温度敏感性のブロック共重合体ヒドロゲル
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
BRPI0809995A2 (pt) * 2007-04-03 2015-07-21 Trimeris Inc Composição, e, métodos para a liberação prolongada de um peptídeo em um paciente e para melhorar um sintoma associado com uma infecção por hiv
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US8067028B2 (en) * 2007-08-13 2011-11-29 Confluent Surgical Inc. Drug delivery device
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
JP2011503707A (ja) * 2007-11-08 2011-01-27 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ コンテンツを管理するための方法及び電子回路装置
WO2009102952A2 (en) * 2008-02-13 2009-08-20 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
JP5150297B2 (ja) * 2008-02-14 2013-02-20 ネクター セラピューティックス エイエル，コーポレイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
CN104961795A (zh) 2008-09-22 2015-10-07 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
WO2010068432A1 (en) 2008-11-25 2010-06-17 Ecole Polytechnique Federale De Lausanne (Epfl) Block copolymers and uses thereof
AU2010204648B2 (en) 2009-01-14 2016-09-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP5890182B2 (ja) 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
LT2440239T (lt) 2009-06-09 2017-12-11 Prolong Pharmaceuticals, LLC Hemoglobino kompozicijos
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
SG178193A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Prodrugs comprising an insulin linker conjugate
SG178195A1 (en) 2009-07-31 2012-03-29 Sanofi Aventis Deutschland Long acting insulin composition
JP2013505300A (ja) 2009-09-22 2013-02-14 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2011051406A1 (en) 2009-10-29 2011-05-05 Ascendis Pharma As Sterilization of biodegradable hydrogels
CA2782899C (en) 2009-12-15 2019-06-11 Incept, Llc Implants and biodegradable fiducial markers
US8524215B2 (en) * 2010-08-02 2013-09-03 Janssen Biotech, Inc. Absorbable PEG-based hydrogels
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
JP2014502152A (ja) 2010-11-12 2014-01-30 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド 癌の治療及び診断
US8440309B2 (en) 2011-01-31 2013-05-14 Confluent Surgical, Inc. Crosslinked polymers with the crosslinker as therapeutic for sustained release
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
EP2768518A4 (en) 2011-10-18 2015-05-27 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES
DK2773334T3 (da) 2011-11-03 2019-12-09 Univ Columbia Sammensætning med forlænget antimikrobiel aktivitet
US9205150B2 (en) 2011-12-05 2015-12-08 Incept, Llc Medical organogel processes and compositions
HK1208039A1 (en) 2011-12-29 2016-02-19 Dana-Farber Cancer Institute, Inc. Stabilized antiviral fusion helices
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
RU2642299C2 (ru) 2012-02-15 2018-01-24 Эйлерон Терапьютикс, Инк. P53 пептидомиметические макроциклы
JP5953459B2 (ja) * 2012-03-27 2016-07-20 ネクター セラピューティクス ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US9395468B2 (en) * 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014039245A1 (en) * 2012-09-07 2014-03-13 The Regents Of The University Of California Method of creating hydrogels through oxime bond formation
RS61957B1 (sr) 2012-09-26 2021-07-30 Harvard College Uvezani peptidi blokirani prolinom i njihove upotrebe
KR101450859B1 (ko) * 2012-10-10 2014-10-15 한국과학기술연구원 염증 억제용 약물을 구비한 신경 전극 및 그 제조 방법
AU2013328785B2 (en) 2012-10-11 2016-07-21 Ascendis Pharma A/S Hydrogel prodrugs
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20150131244A (ko) 2013-03-13 2015-11-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
WO2014151369A2 (en) 2013-03-15 2014-09-25 Dana-Farber Cancer Institute, Inc. Stabilized ezh2 peptides
WO2014144768A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Bh4 stabilized peptides and uses thereof
US10087215B2 (en) 2013-03-15 2018-10-02 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
BR112015031277A2 (pt) 2013-06-14 2017-09-19 Harvard College Moduladores do receptor de insulina de polipeptídeos estabilizados, análogos de insulina, composições farmacêuticas compreendendo os referidos polipeptídeos e métodos de preparação e usos dos mesmos
US10711106B2 (en) 2013-07-25 2020-07-14 The University Of Chicago High aspect ratio nanofibril materials
AU2014348502B2 (en) 2013-11-15 2019-08-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
EP3145523A4 (en) 2014-05-21 2018-02-21 President and Fellows of Harvard College Ras inhibitory peptides and uses thereof
BR112017000813B1 (pt) 2014-07-17 2021-03-16 The Regents Of The University Of California sistemas de gel microporoso, usos de uma pluralidade de partículas de microgel em uma solução aquosa e um agente de recozimento, de camadas de sequestrantes covalentemente estabilizados de partículas de microgel, e de um sequestrante covalentemente estabilizado de partículas de microgel com espaços intersticiais, bem como método para a preparação de partículas de microgel
CN107106642B (zh) 2014-09-24 2021-02-26 艾瑞朗医疗公司 拟肽大环化合物及其制剂
EP3197478A4 (en) 2014-09-24 2018-05-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3229851A4 (en) 2014-12-09 2018-08-01 Tangible Science LLC Medical device coating with a biocompatible layer
US11142554B2 (en) 2015-03-18 2021-10-12 Massachusetts Institute Of Technology Selective Mcl-1 binding peptides
JP2018516844A (ja) 2015-03-20 2018-06-28 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその使用
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2989311A1 (en) 2015-07-02 2017-01-05 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
US20190002506A1 (en) 2015-08-28 2019-01-03 Dana-Farber Cancer Institute, Inc. Stabilized peptides for covalent binding to target protein
EP3341008B1 (en) 2015-08-28 2026-04-15 Dana-Farber Cancer Institute, Inc. Peptides binding to bfl-1
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
JP6184462B2 (ja) * 2015-10-28 2017-08-23 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US11931480B2 (en) 2016-02-16 2024-03-19 The Regents Of The University Of California Microporous annealed particle gels and methods of use
CN109069578A (zh) 2016-02-29 2018-12-21 达纳-法伯癌症研究所股份有限公司 用于治疗感染的钉合的细胞内靶向抗微生物肽
JP6925579B2 (ja) 2016-03-31 2021-08-25 日油株式会社 環状ベンジリデンアセタール構造を有する生分解性ヒドロゲル
WO2017200818A1 (en) * 2016-05-16 2017-11-23 The Trustees Of Columbia University In The City Of New York Coatings and methods for infection-resistant medical devices
US11198715B2 (en) 2016-07-22 2021-12-14 Massachusetts Institute Of Technology Selective Bfl-1 peptides
AU2017315447B2 (en) 2016-08-26 2023-04-27 Dana-Farber Cancer Institute, Inc. Bcl-w polypeptides and mimetics for treating or preventing chemotherapy-induced peripheral neuropathy and hearing loss
JP7042053B2 (ja) 2016-10-07 2022-03-25 国立大学法人東京工業大学 分岐型ヘテロ単分散ポリエチレングリコール、その製造方法、及びその結合体
EP3551213A4 (en) 2016-12-07 2020-11-04 The University of Chicago FOX3 INHIBITION COMPOSITIONS AND METHODS
AU2017394923B2 (en) 2016-12-29 2022-07-14 Tempo Therapeutics, Inc. Methods and systems for treating a site of a medical implant
WO2018170299A1 (en) 2017-03-15 2018-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitors of prokaryotic gene transcription and uses thereof
JP6361083B2 (ja) * 2017-06-27 2018-07-25 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
AU2018383633B2 (en) 2017-12-15 2024-05-16 Dana-Farber Cancer Institute, Inc. Selective targeting of apoptosis proteins by structurally-stabilized and/or cysteine-reactive NOXA peptides
WO2019118893A1 (en) 2017-12-15 2019-06-20 Dana-Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019157131A1 (en) 2018-02-07 2019-08-15 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US20200408746A1 (en) 2018-03-14 2020-12-31 Dana-Farber Cancer Institute, Inc. Stabilized Peptides for Biomarker Detection
JP6500318B2 (ja) * 2018-04-04 2019-04-17 ウェルズ ファーゴ バンク ナショナル アソシエイション ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
CN109939065B (zh) * 2018-08-10 2021-08-03 上海瑞凝生物科技有限公司 医用水凝胶
WO2020060975A1 (en) 2018-09-17 2020-03-26 Massachusetts Institute Of Technology Peptides selective for bcl-2 family proteins
CA3116906A1 (en) * 2018-11-02 2020-05-07 Bionaut Labs Ltd. Magnetomechanic triggering of payload release from miniaturized devices
EP3962933A1 (en) 2019-04-18 2022-03-09 Dana-Farber Cancer Institute, Inc. Selective targeting of ubiquitin- and ubiquitin-like e1-activating enzymes by structurally-stabilized peptides
US20210059933A1 (en) * 2019-08-29 2021-03-04 Paul Douglas Godfrin Hydrogels as oral delivery dosage forms, methods of making and using same
WO2021071927A1 (en) * 2019-10-08 2021-04-15 Incube Labs, Llc Controlled release formulation delivery device
EP4077361A1 (en) 2019-12-16 2022-10-26 Dana-Farber Cancer Institute, Inc. Structurally-stabilized oncolytic peptides and uses thereof
AU2020408070A1 (en) 2019-12-20 2022-06-09 Dana-Farber Cancer Institute, Inc. Structurally-stabilized glucagon-like peptide 1 peptides and uses thereof
EP4114431A2 (en) 2020-03-04 2023-01-11 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof
WO2021216845A1 (en) 2020-04-22 2021-10-28 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ace2 helix 1 peptides and uses thereof
EP4142766A2 (en) 2020-04-27 2023-03-08 Dana Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
WO2022013642A1 (en) 2020-07-16 2022-01-20 3M Innovative Properties Company Phosphate-containing copolymers for virulence suppression
AU2021360898A1 (en) 2020-10-14 2023-03-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use
EP4240395A1 (en) 2020-11-05 2023-09-13 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized ebolavirus peptides and uses thereof
US12552834B2 (en) 2021-01-25 2026-02-17 Massachusetts Institute Of Technology Selective MENA binding peptides
CN114907580B (zh) * 2021-02-09 2024-11-29 上海瓴就医疗科技有限公司 一种可降解的双组份水凝胶及其制备方法与应用
WO2023039474A1 (en) 2021-09-08 2023-03-16 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stapled sars-cov-2 peptide- cholesterol conjugates and uses thereof
EP4518900A1 (en) 2022-05-04 2025-03-12 Dana-Farber Cancer Institute, Inc. Ebolavirus surface glycoprotein peptides, conjugates, and uses thereof
CN114767920B (zh) * 2022-05-13 2023-08-29 中国科学院长春应用化学研究所 一种聚乙二醇基粘合剂及其制备方法以及应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3149006A (en) 1963-01-31 1964-09-15 William T Abel Prevention of embrittlement of metals
US3419006A (en) 1966-08-08 1968-12-31 Union Carbide Corp Novel dressing and use thereof
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3963805A (en) 1974-10-30 1976-06-15 Union Carbide Corporation Water swellable poly(alkylene oxide)
AU537741B2 (en) 1979-03-21 1984-07-12 British Technology Group Limited Controlled release compositions
JPS585320A (ja) 1981-07-01 1983-01-12 Toray Ind Inc グラフト共重合体
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5626863A (en) 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5192743A (en) 1992-01-16 1993-03-09 Genentech, Inc. Reconstitutable lyophilized protein formulation
US5573934A (en) 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5334640A (en) 1992-04-08 1994-08-02 Clover Consolidated, Ltd. Ionically covalently crosslinked and crosslinkable biocompatible encapsulation compositions and methods
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
US5514379A (en) † 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
AU4899093A (en) 1992-10-13 1994-04-28 Pacesetter Ab Compound and method of applying anti-fouling coatings on medical devices
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
DE4342154A1 (de) 1993-12-10 1995-06-14 Behringwerke Ag Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
US5618528A (en) 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5730968A (en) 1994-03-31 1998-03-24 Sterling Winthrop Inc. Segmented chelating polymers as imaging and therapeutic agents
JPH10501814A (ja) * 1994-06-17 1998-02-17 ユニバーシティ・オブ・ネブラスカ・ボード・オブ・リージェンツ 生物的作用物質用のイン・シツゲル形成デリバリービヒクルおよびその使用方法
WO1996020012A2 (en) 1994-12-23 1996-07-04 Middlesex Sciences, Inc. Methods for preparing and purifying macromolecular conjugates
US5962023A (en) * 1995-03-06 1999-10-05 Ethicon, Inc. Hydrogels containing absorbable polyoxaamides
US5698213A (en) * 1995-03-06 1997-12-16 Ethicon, Inc. Hydrogels of absorbable polyoxaesters
US5607687A (en) 1995-03-06 1997-03-04 Ethicon, Inc. Polymer blends containing absorbable polyoxaesters
US5648088A (en) * 1995-03-06 1997-07-15 Ethicon, Inc. Blends of absorbable polyoxaesters containing amines and/or amide groups
US5597579A (en) 1995-03-06 1997-01-28 Ethicon, Inc. Blends of absorbable polyoxaamides
PT876165E (pt) 1995-12-18 2006-10-31 Angiotech Biomaterials Corp Composicoes de polimeros reticulados e processos para a sua utilizacao
US5610241A (en) 1996-05-07 1997-03-11 Cornell Research Foundation, Inc. Reactive graft polymer with biodegradable polymer backbone and method for preparing reactive biodegradable polymers
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6258351B1 (en) 1996-11-06 2001-07-10 Shearwater Corporation Delivery of poly(ethylene glycol)-modified molecules from degradable hydrogels
WO1999034833A1 (en) 1998-01-07 1999-07-15 Shearwater Polymers, Incorporated Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom

Also Published As

Publication number Publication date
DE69837443D1 (de) 2007-05-10
CA2303365C (en) 2007-08-21
PT1019446E (pt) 2007-06-25
US7964217B2 (en) 2011-06-21
DK1019446T4 (da) 2012-03-19
US20040076602A1 (en) 2004-04-22
DE69837443T2 (de) 2008-04-17
EP1019446A1 (en) 2000-07-19
ES2281925T5 (es) 2012-04-13
DE69837443T3 (de) 2012-05-24
JP2001518528A (ja) 2001-10-16
CA2303365A1 (en) 1999-03-25
ATE358150T1 (de) 2007-04-15
EP1019446B2 (en) 2011-11-30
JP4083384B2 (ja) 2008-04-30
ES2281925T3 (es) 2007-10-01
WO1999014259A1 (en) 1999-03-25
US20020064546A1 (en) 2002-05-30
EP1019446B1 (en) 2007-03-28
AU6029398A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
DK1019446T4 (da) Nedbrydelige poly(ethylenglycol)hydrogeler med styret halveringstid og prækursorer dertil
DK1028753T3 (da) Indgivelse af poly(ethylenglycol)-konjugerede molekyler fra nedbrydellige hydrogeler
DE60033969D1 (de) Hydrolytisch abbaubare carbamatderivate von polyethylenglykol
Bouhadir et al. Synthesis of cross-linked poly (aldehyde guluronate) hydrogels
EP1374908A2 (en) Polymer-drug conjugates comprising hydrazide linkers
BRPI0418309B8 (pt) "géis coesos de hialuronado e/ou hilano reticulados, processo para a preparação dos mesmos, bem como composições e dispositivos compreendendo os referidos géis".
WO2004110358A3 (en) Polymeric conjugates for tissue activated drug delivery
ES2173943T3 (es) Sulfonas activas de polietilenglicol solubles en agua.
ATE349202T1 (de) Formulierung auf heparin-, glycosaminoglykan- oder heparinoidbasis und verwendung der formulierung sowie der formulierungsgrundlage
WO2003097107A3 (en) Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
ATE499116T1 (de) Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
DE69523044D1 (de) Block- und pfropfcopolymere und dazu gehöriges verfahren
DE60017831D1 (de) Dermale zusammensetzungen
WO2004112713A3 (en) Drug polymer complexes
Gerrits et al. Semiflexible polymer scaffolds: an overview of conjugation strategies
SE8503486D0 (sv) Tverbundna geler av hyaluronsyra, metod for framstellning av sadana geler och produkter som innehaller sadana geler
NO934489L (no) Kompleksdanner for gallesyre
EP1773399B1 (en) Hydrogels of hyaluronic acid and alpha, beta-polyaspartylhydrazide and their biomedical and pharmaceutical uses
Mahkam Starch‐based polymeric carriers for oral‐insulin delivery
EP0780419A1 (en) Multi-functional site containing polymers, and applications thereof
EP0838224A3 (en) Polymer-drug conjugates with an enzyme cleavable linker
Zhang et al. Crosslinked poly (ethylene glycol) hydrogels with degradable phosphamide linkers used as a drug carrier in cancer therapy
Henkel et al. DNA Crosslinked Mucin Hydrogels Allow for On‐Demand Gel Disintegration and Triggered Particle Release
NO20030073L (no) Medikamentleveringssystem for medikamenter som er lite vannopplöselige
Sockett et al. Clickable polyamidosaccharides